The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is widely used in retroviral gene transfer vectors. However, this element contains an open-reading frame (ORF) encoding a truncated peptide of the woodchuck hepatitis virus X protein (WHX). Because we are developing a lentiviral vector for the gene therapy of Wiskott-Aldrich syndrome (WAS), we evaluated whether the WPRE was needed in the gene transfer cassette and tested the possibility of replacing it with a mutated derivative. The transcriptional activity of the WPRE was undetectable in the context of the lentiviral vector but the element was capable of translating a polypeptide. This capability was abrogated by mutating the WHX ORF translation start. The WPRE was required to express high levels of the transgene and for that, the native form or mutated derivatives functioned equivalently. The vector using a WAS gene promoter and the mut6 WPRE induced long-term expression of the WAS transgene in vivo, correcting cytoskeletal defects, thymocyte and B-cell numbers and improved the colitis of WAS-null mice. By providing additional evidence of efficacy of this WAS lentiviral vector with improved safety features, our results validate a mutated WPRE, which should be useful in future gene therapy applications.
Introduction
The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is a hepadnavirus sequence that is widely used as a cis-acting regulatory module in various types of plasmid or viral gene vectors. [1] [2] [3] [4] [5] The WPRE is often essential to achieve sufficient levels of expression with integrative retroviral vectors configured for gene therapy; therefore, its mechanisms of action have been studied in detail. When placed in the 3 0 untranslated region of gene transfer cassettes, the WPRE enhances the expression of the transgene by increasing both nuclear and cytoplasmic mRNA levels, early during the biogenesis of RNA transcripts. 2, 6 Although the WPRE is coupled in part to the CRM1-dependent export machinery, 7 its posttranscriptional effects do not result from increased RNA export or from an increased rate of transcription or longer half-life of RNA species but rather from improved 3 0 end transcript processing. The WPRE seems to increase the amount of polyadenylated transcripts and clearly augments the size of the polyA tail of RNA. 8 The polyA motifs are contained in the long terminal repeats (LTRs) of gammaretroviral or of human immunodeficiency virus (HIV)-1-derived gene transfer cassettes. When placed upstream of the 3 0 LTR, the WPRE improves transcript termination and therefore can significantly reduce transcript read-through, particularly with Moloney-derived vectors. 6, 8 Probably in part through this effect, the WPRE can also augment the titers of viral preparations although results are variable and the exact mechanisms underlying this effect remain to be determined. 6, 8 The magnitude of the effects of WPRE vary upon the specific context of the promoter, transgene and cell type, and this has been shown both for its effects on transgene expression 4 or viral titers. 3, 6, 8 For this reason, the effects of this 3 0 regulatory element need to be evaluated in specific contexts.
For the gene therapy of Wiskott-Aldrich syndrome (WAS), we have developed an HIV-1-derived selfinactivating (SIN) lentiviral vector (LV) encoding a cDNA of the human WAS gene. To express this cytoskeletal regulator, the expression cassette employs native WAS gene regulator sequences that are not as potent as many other heterologous promoters used in gene transfer vectors. 9 A WPRE was inserted in the 3 0 region of the gene transfer cassette to ensure optimal levels of the WAS transgene expression, although it was not known whether it was absolutely required. This vector efficiently induces the expression of the WAS protein (WASp) in several types of hematopoietic cells, including T cells, B cells, dendritic cells and CD34 + cells. 9 In gene therapy models, this vector can correct the defective function of murine WASp-deficient T cells over sustained periods of time in vivo. 10 The application of gene therapy to humans requires a thorough assessment of the safety of the genetic elements that will become permanently integrated in the genome of the patient's cells. The WPRE has been under scrutiny because its sequence overlaps with that of the woodchuck hepatitis virus X protein (WHX), which is a transcriptional activator of about 150 AA implicated in the development of liver tumors. 11 The WPRE inserted in most vectors contains the WHX gene promoter and an open-reading frame coding for the first 61 AA of WHX in its 3 0 region. There is no direct evidence that such polypeptide could be expressed or functional when inserted in a heterologous transcription unit like a vector. However, this polypeptide represents about 80% of the C-terminally truncated sequences of the X protein gene that were retrieved from liver tumors containing integrated woodchuck hepatitis virus (WHV) or hepatitis B virus (HBV) genome. 12 The C-terminal portion of the X protein is important in regulating its effects on cell proliferation and viability. C-terminal truncated mutants, although not oncogenic by themselves, can cooperate with the ras and myc oncogenes, suggesting that these truncated sequences may have a function in the tumorigenesis of HBVs. 13 These indirect arguments led to suspicion that WPRE sequences contributed to hepatocellular carcinomas observed in mice treated with an equine infectious anemia virus-derived LV containing this element. 11 Subsequently, controlled experiments did not support this hypothesis because control mice treated with HIV-derived LVs bearing the same WPRE or a WPRE mutated at the X gene promoter and start codon did not develop tumors. 14 Nevertheless, this has prompted us to assess the WPRE inserted in our WASp-encoding LV to determine (1) if a WHX coding sequence could be expressed from this vector in the target hematopoietic cells, (2) if the WPRE element was required in this particular WASp gene transfer vector and (3) if a mutated WPRE invalidated for protein X production could be used instead of the wild-type (WT) WPRE. Results presented herein support the need for a WPRE in this WASp LV to increase transgene expression and show that a mutated WPRE functions equivalently to the WT counterpart in vitro and in vivo, allowing high and sustained transgene expression while abrogating WHX protein synthesis.
Results

Characterization of WPRE mutants that abrogate the translation of a WHX polypeptide
The so-called WT WPRE present in many RNA vectors is encoded by a 591-bp sequence (nucleotides 1094-1684 in GenBank accession number J02442) containing a portion of the WHV X protein open-reading frame (ORF) in its 3 0 region ( Figure 1a) . To assess the transcriptional and translational capacity of the element, we generated mutants in the WHX promoter and/or translation start sequence as indicated in Figure 1a . One mutant, called mut6, contains six-point mutations located in the start codon and putative promoter region of WHX. This mutated element has already been used in some gene transfer vectors, 14, 15 but its characteristics have not yet been systematically evaluated. Another mutant, called mut1, consisting of a single nucleotide mutation in the WHX protein translation start, was generated for this study. To easily detect the production of WHX polypeptide from the constructs, we created an experimental model consisting in the fusion of an ATG-less enhanced green fluorescent protein sequence (aGFP) 3 0 of the various tested WPRE elements and in-frame with the indicated WHX ORF translation start. The various WPRE/aGFP constructs, containing either the WT, mut6 or mut1 sequences fused to aGFP, were tested for transcriptional and translational activities.
To assess the transcriptional activity, we inserted the different WPRE/aGFP fusions into a plasmid devoid of eukaryotic promoter as schematized in Figure 1b , I. The negative control lacked entirely the WPRE upstream of the modified GFP (pdelta/aGFP). Equal amounts of the various plasmids were transfected into HCT116 cells and after 48 h, WHX mRNA expression was quantified by quantitative real-time PCR (qRT-PCR) in relation to the human cellular gene PO (Figure 2a) . The experiment was controlled with the transfection of a lentiviral phosphoglycerate kinase (PGK)-GFP plasmid cassette (Figure 1b , IV) providing the arbitrary value of 1.0 for mRNA expression. Transfection with the pWPRE/aGFP plasmids containing the WT, mut6, mut1 or delta-WPRE expressed, respectively, 1.4, 1.1, 1.2 or 0 of this arbitrary value (Figure 2a) . These results confirm the presence of a promoter activity in the WPRE but also suggest that this promoter activity is not invalidated in the mut6 mutant.
The translational activity of the WPRE was assessed by measuring GFP expression in these transfected cells. Significant levels of GFP expression were detected following transfection with the pWPRE/aGFP plasmid containing the WT WPRE (Figure 2b ), although the percentage of positive cells and the mean fluorescence intensity (mfi) remained lower than in the positive control. In contrast, plasmids containing the mut6 or mut1 elements gave background fluorescence levels as in nontreated cells or cells transfected with the pdelta/ aGFP plasmid lacking the WPRE. Altogether, these results show that the unmodified WPRE can be active at the transcriptional and translational level. In the context of these plasmid constructs, both mut1 and mut6 mutants retain a promoter activity but have lost the ability to translate a WHX polypeptide.
Because the effects of the WPRE are context dependent, we assessed its translational and transcriptional activities in the context of a lentiviral gene transfer cassette. We have characterized an advanced generation SIN LV for the expression of the WASp under control of the WAS gene promoter. However, to compensate for the relatively weak activity of the promoter, a WPRE was added for 3 0 end processing. To assess the activity of this element in the specific context of the WAS LV, we constructed the pLV-W-W-WPRE/aGFP series of transfer Validation of a mutated PRE MA Zanta-Boussif et al cassettes that are depicted in Figure 1b , II, fusing to aGFP either the WT, mut6, mut1 or no WPRE. LV particles produced with these constructs were used to transduce cell lines of various origins: a colon carcinoma cell line (HCT116 cells), the hepatocyte cell line (HepG2 cells) or a B-lymphoblastic cell line (B-LCL). The positive controls were transduced with LV PGK-GFP viral particles. Significant levels of GFP were detected in all cell lines following transduction with LV-W-W-WPRE/aGFP vectors containing the WT WPRE (Figure 3 ), although the levels were not as high as those obtained with the positive control, as shown by lower mfi values. In contrast, no GFP was detectable in cells transduced with vectors containing either the mut6 or mut1 WPRE. In such conditions, the fluorescence levels were similar to the background observed with the LV lacking the WPRE/aGFP. To assess the levels of transcription from the WPRE as cloned in the context of the preclinical WAS LV, we constructed LV-W-W-WPRE vectors (Figure 1b, III) with either the WT, mut1, mut6 or no (delta) WPRE and produced the corresponding viral particles. In cells transduced with these vectors, the WHX and WAS sequences are expected to be both expressed from a single transcript driven by the WAS promoter and interrupted at the natural polyA sequence of the 3 0 LTR, but the WPRE may additionally be transcribed from its own promoter. Figure 1 (a) Modifications of woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) sequence in WAS protein (WASp)-lentiviral vector. WPRE sequence in lentiviral vectors used in this study is constituted of a 591-bp DNA sequence containing the promoter region of woodchuck hepatitis virus (WHV) X protein followed by a truncated form of the X protein itself starting in position 1502 based on GenBank accession number J02442. Modifications of the wild-type WPRE sequence generated the mutant mut6, containing five-point mutations in the putative promoter region and 1 nucleotide change in the start codon of X protein ORF; the mut1 mutant containing only single-point mutation in the start codon. (b) Schematic representation of the various constructs used in the study. In the series of constructs I, II and III, the plasmids contain either the WPRE in a wild-type, mut6 or mut1 form. As controls, plasmids lacking the entire WPRE sequence were also used and called 'delta-WPRE'. In the series I and II, the cDNA of the enhanced green fluorescent protein (eGFP) lacking the ATG start codon (aGFP) was fused to the open-reading frame (ORF) of the putative X protein to generate a X protein/GFP chimeric transcript. In the series I, the human B2 globin intron and polyadenylation sequences (polyA) were used as a polyadenylation signal, whereas in series II, III and IV, the polyadenylation signal is contained with lentiviral 3 0 LTR. The lentiviral vectors are self-inactivated and expressed from plasmids bearing a heterologous 5 0 U3 region containing the Rous sarcoma virus (RSV) promoter and the 3 0 LTR contains a 400 bp deletion in the U3 region. The backbone contains the encapsidation signal (c and Dgag), the Rev responsive element (RRE), the central polypurine tract with its termination sequence (cPPT/cTS) and encodes either the human WAS or the eGFP cDNA followed by the WPRE in various forms, or no WPRE. A signal was detected when the wild-type (WT) form of woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was used, whereas the signal decreased to background level when the mutated WPRE forms were used as observed with delta-WPRE constructs.
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MA Zanta-Boussif et al sequences and was not invalidated by the five-point mutations in this putative promoter region as shown with the mut6 derivative. This promoter activity was not detectable in the context of the LV suggesting that in this context it is probably masked. We cannot exclude that such promoter activity remains undetectable in other types of expression systems and configurations. In spite of the lack of detectable promoter activity, the native WPRE has the capacity to generate a polypeptide translated from the WHX ORF when inserted in the context of LV cassettes integrated in target hematopoietic cells. This capacity is abrogated by single-point mutations in the start codon as in mut1 and mut6 mutants. So, in the WAS LV, the WAS promoter can drive transcription of the WPRE but no WHX protein is produced when start codon mutations are introduced this element.
The WPRE does not affect viral titer but enhances the levels of expression of the WASp transgene
Preclinical efficacy studies for the gene therapy of WAS have been initially conducted with a WASp-encoding LV containing a WT WPRE. 9,10 However, it is not known if this element is actually needed for transgene expression or for producing high titers of vector. We produced three independent batches of vesicular stomatitis G protein (VSV-G)-pseudotyped lentiviral particules with each of the pLV-W-W-WPRE coding for WASp and containing either the WT, mut6, mut1 or no WPRE (Figure 1b, III) . The titers of these various vector batches were comparable and were not significantly different if the WPRE was present or not (Table 2) . These results are consistent with those of Schambach et al. 8 reporting that variable Validation of a mutated PRE MA Zanta-Boussif et al effects of the WPRE on titers were observed according to the LV construct.
The effects of the WPRE on transgene expression in target cells were examined following transduction of WAS patient B-cell lines with the various vectors containing or not containing WPRE and by measuring protein levels in western blots (Figures 4a and b) . One of the blots is illustrated in Figure 4a . The quantification of the levels of WASp relative to a stable housekeeping reference in three independent experiments showed that equivalent levels were obtained when any of the WPRE was used whereas statistically lower levels were obtained when the WPRE was absent from the vector (Figure 4b) . Therefore, the WPRE does not seem to be needed for producing high titers of the WAS LV. However, this element seems to be required to obtain high levels of transgene expression in target cells with this vector and for that, the native or mutated forms can be used equivalently.
Equivalent transgene expression in vitro and in vivo from vectors with the WT or mutated WPRE
To validate that the mut6 mutant could be used in the WAS vector instead of the native WPRE, we performed comparative experiments in vitro and in vivo. Following in vitro transduction of WAS patient-derived B-LCL with various concentrations of LV, we observed that vectors with the WT and mut6 WPRE provided similar levels of transgene expression over a wide range of vector concentrations tested and as measured by WAS mRNA (Figure 4c ) and protein levels in the transduced cells ( Figure 4d) .
Next, we conducted in vivo gene transfer experiments in the murine model described previously. 16 Two independent transplantation experiments were performed with two different batches of each vector carrying either the native or the mut6 WPRE. Bone marrow (BM) lineage-negative (Lin À ) hematopoietic progenitor cells from WASp-null mice (WKO, WAS knockout, mice) were transduced with each of the WAS LV during a short ex vivo culture. Such cells were then transplanted into lethally irradiated WASp-deficient females. A fraction of these Lin À cells was analyzed at this point showing that either of these WAS vectors had induced equivalent vector copy number (VCN) (data not shown), equivalent levels of WASp protein expression (Figure 5a ) as well as equivalent levels of human WAS mRNA (Figure 5b ) in the cultured cells. The hematopoietic and genetic reconstitution of the transplanted mice was assessed in the first 2 months after transplantation and showed comparably high percentage of male/ female chimerism and of VCN in circulating blood cells in groups of mice treated with either one of the WAS LV, indicating that the grafts were equally successful ( Figure  5c ). Mice were then killed between 2 and 4 months to examine short-term effects of the transduction. Stable engraftment of the cells was confirmed because all groups treated with control vectors or with the WAS vectors had comparable levels of chimerism in the BM or in the spleen tissues (Figure 5d ). The level of transduction and gene expression in these tissues is shown in Table 3 that shows the WAS LV containing either the WT or mutant WPRE functioned equivalently in vivo. Comparable levels of transgene expression and equivalent levels of transduction were found in the BM or in the spleen of the animals treated with either of the WAS LV. In addition, some mice were kept for 8.5 months to examine their long-term hematopoietic reconstitution. These animals showed that the WAS LV continued to be expressed and in particular that a vector containing the mut6 WPRE can provide sustained transgene expression in vivo (Table 3) .
Equivalent functional restoration with WASp-encoding vectors containing the WT or mutated WPRE
To evaluate the functional correction of gene therapy in this model, we first examined the restoration of cytoskeletal function as evaluated by podosome formation in bone marrow-derived dendritic cells (BM-DC) upon adherence onto fibronectin. The formation of podosomes is defective in WKO cells both quantitatively and qualitatively. Fewer cells exhibit these structures and when they do, they make small clusters and have fewer total podosomes per cell than controls. 17 We have previously reported that podosomes are restored in immature dendritic cells following ex vivo gene therapy in WKO mice with an LV expressing the WAS transgene from the PGK promoter. 16 As shown in Table 4 , mice (Figure 5e ). Transduction of the WKO cells with the WAS LV resulted in the restoration of high levels of immature thymocytes in most mice, indicating a correction of thymopoiesis by ex vivo gene therapy. It is to our knowledge the first time that this defect is reportedly corrected by an ex vivo gene transfer approach in a model of WAS. This was obtained with vectors containing either form of the WPRE. Spleen cells were also analyzed to measure B-cell numbers that are reportedly reduced in WKO mice compared to WT littermates. 18 Indeed, we found a precipitous drop in the percentage of B200 + cells in the spleens of mice that were recipient of uncorrected WKO cells compared to mice treated with WT cells (Figure 5f ). This defect was partially but clearly corrected when mice received Table 3 ). (e) In one experiment, mice were killed 2 months after transplantation to examine thymopoiesis by flow cytometric analysis of CD4 and CD8 expression (top panel). Ex vivo gene transfer resulted in higher levels of double-positive thymocytes and comparable effects were obtained regardless of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). (f) In other experiments, mice were killed 4 months after transplantation to examine B-cell counts in the spleen using flow cytometric determination of B220 + cells (bottom panel). Each dot represents a mouse, and gray and black dots distinguish two separate transplantation experiments. Statistically significant differences were found between the control WAS-KO and each of the lentivirus-treated groups (*bilateral Student's t-test, Po0.05), whereas differences between LV treatment groups were not significant (NS).
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MA Zanta-Boussif et al therapy with an LV expressing WASp from the PGK promoter is also capable of resolving the colitis in this model. 16 Here, we evaluated if the LV using the WAS gene promoter and either form of the WPRE would also provide such benefit. The colon of mice treated for 4 or 8.5 months was examined. As expected, the colon of mice treated with WT cells was normal (Table 5 and Figure 6a ) whereas a strong inflammatory colitis was seen in mice given uncorrected WKO cells as characterized by abnormal mucosal architecture, atrophic mucosal wall, dysplastic glands and a polymorphic inflammatory infiltration in the mucosa that often spread to the thickened muscular wall (Figure 6b ). Mice treated with the WAS LV were significantly ameliorated by the treatment. Usually only focal or mild defects persisted and some of the gene-therapy-treated animals displayed normal colon histology (Table 5 and Figures 6c and d) . Well-differentiated, secretory and noninflammatory mucosa were also observed in these animals at late time points (8.5 months) after treatment. In one experiment, the efficacy of the ex vivo gene therapy was also confirmed by observing a clear reduction in diarrhea in the animals (data not shown). Similar levels of correction were seen in mice treated with vectors containing either the native or the mutated WPRE (Table 5 and Figures 6c  and d) . In summary, our data show that vectors with the mut6 WPRE adequately function in vivo for extended periods of time to ensure high levels of transgene expression and functional correction in a murine model of ex vivo gene therapy for WAS.
Discussion
The development of a gene therapy for WAS has provided a context to characterize the WPRE element and to demonstrate the activity of an LV with improved safety features. We show that the native WPRE that is used in most gene therapy vectors has the potential to encode an ORF in a setting that is relevant to gene Results are expressed as the number of mice for which the colons score in each of the three criteria used for histological analysis. 
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MA Zanta-Boussif et al capacity, we do not know if the native WPRE produces similar amounts of the truncated WHX polypeptide than of WHX-GFP fusion polypeptide. We could not specifically detect the truncated WHX to assess this point. The WPRE also displayed an intrinsic promoter activity but it was not detected in all conditions. This promoter activity was clearly detectable in constructs lacking other promoter sequences. In this context it was possible to assess the impact of the five-point mutations in this putative promoter region. These mutations, which were designed following a study of the tripartite structure of the WHV PRE, 1 failed to abrogate the transcriptional activity of the WPRE, suggesting that either the mutated sequence remains operational or that there are additional promoter sequences in the element. The failure to invalidate this promoter may not have relevant consequences because the promoter activity of the WPRE could not be detected in the LV integrated in hematopoietic or nonhematopoietic cells. We speculate that this may be due to interference with the internal promoter of the vector, as is often described between nearby promoter sequences.
On the basis of our results, the mut6 WPRE could be recommended in place of the native element for various gene therapy vectors. This mutant WPRE has been inserted in a Moloney-derived gene therapy vector for ADA-SCID treatment, which is currently in the clinic with positive results. 15 Other safer alternatives to the native WPRE exist. A safe and functional PRE was designed by deleting the 3 0 region to remove all remnants of the X protein or its promoter and to mutate the remaining ATGs throughout the element to remove any putative ORF larger than 25 AA. 21 Such minimal PRE functions effectively to increase viral titer and to enhance gene expression in gammaretroviral and LVs. To our knowledge, it has not yet been reported how this truncated WPRE compares in the long run with the native element in in vivo gene therapy models.
The effects of the WPRE are known to be context dependent. For the gene therapy of WAS, we developed a vector with increased safety features, using the native WAS gene promoter to ensure a physiological regulation of expression of the transgene. 9 Such a cellular internal promoter is not only more physiological but also should minimize the risk of insertional mutagenesis as described with the use of cellular promoters. 22 In the specific context of the WAS LV, we show that the WPRE is required to obtain an adequate expression of the WAS transgene, although it does not seem to be required for the production of high viral titer. We also show that either of the mutant tested can be used to replace the native WPRE to express equivalent levels of transgene. The mut6 WPRE was extensively compared to the native element in various assays notably in vivo. These tests confirmed that they were equivalent because no significant difference was observed in their capacity to transduce cells, or to express the transgene to functional levels and over time. These studies provided novel observations on the correction of diverse malfunctions of WKO animals by the WAS LV. So far, the WAS LV had been essentially assessed in vivo for the correction of mature T-cell activation and functional defects. 10 Here we report that an amelioration or a complete correction of the autoimmune inflammatory colitis has been obtained in all animals following gene therapy with the WAS LV. Such effect would be consistent with the correction of WASp expression in T cells and the normalization of their T-helper and regulatory functions, because TH2 cells and regulatory T cells have a major function in the development and control of the autoimmune colitis in this model. 20, 23 The correction of colitis provides an important preclinical validation for the WAS LV and confirms the effects that we had previously reported with an LV expressing the WAS transgene under control of the PGK promoter. 16 Although the WAS gene promoter is weaker than the PGK promoter, it generates equivalent levels of protein WASp in transduced cells, as reported previously. 9 This is confirmed here, because we find comparable therapeutic efficacy of vectors using either the WAS or PGK promoters in this in vivo setting. The improvement in autoimmune colitis has also been obtained following transplantation of retrovirally transduced BM cells utilizing a strong viral LTR promoter to express the WAS transgene. 24 Altogether these results suggest that a strong promoter system does not appear to be essential to express the WAS transgene to obtain significant therapeutic benefit. Besides the improvement of the colitis, we also report that the WAS LV can increase the thymopoiesis in BM-reconstituted mice. The vector also corrects non-T-cell defects as it restores podosomes in BM-DC and augments the numbers of splenic B cells in the model. These effects of ex vivo gene therapy on lymphoid cell homeostasis have not yet been reported. A selective advantage of WASp-expressing B cells has only been reported very recently and is likely to explain our results. 25 These novel observations consolidate and extend the existing preclinical data to show that ex vivo gene therapy with the WAS LV is expected to correct multiple lineages of immune cells and could provide a therapeutic benefit notably by reducing the pathophysiological signs of autoimmunity. Biosafety studies in normal or tumor-prone mice could potentially assess the potential genotoxicity of the vector and of its components in sensitive models. 26 As the WPRE carries enhancer sequences this seems particularly important. Additional experiments, beyond the scope of this paper, have already evaluated the biosafety of ex vivo gene therapy in WASpnull mice. In long-term observation or secondary transplant models in mice, the WAS LV bearing the mut6 WPRE caused no observable hematopoietic toxicity. 27 This strongly supports the development of this LV toward clinical application. The presence of the mut6 WPRE in addition to the WAS promoter in such a vector constitutes two important safety feature for this objective.
Materials and methods
Plasmid constructions
To generate the WPRE/aGFP fusions, the WT WPRE element was first obtained by PCR as a EcoRV/EcoRV fragment from the pRRL SIN cPPT-PGK-eGFP WPRE plasmid (kind gift from Dr L Naldini, Tiget, Milan) (forward primer 5 0 -GGGGATATCAATCAACCTCTGG A-3 0 and reverse primer 5 0 -CCCGATATCAGGCGGGGA GGCGG-3 0 ) and was first inserted in the corresponding sites in the pBA vector. The fusion between the truncated WHX protein and eGFP ORFs was then obtained by generating a 103-bp PCR fragment spanning from the SacII restriction site of WPRE to the end of WPRE 0 -AGCTCTCGAGACCTCTACAAATGTGGTAT GGC-3 0 ). SacII-WPRE/aGFP fragments were digested with SacII and XhoI and inserted in the corresponding sites of pBA-WPRE. The pWPRE(WT)/aGFP construct was obtained by excising the CMV promoter from the pBA-WPRE with BamHI digestion and self-ligation.
The mut1 element was obtained by site-directed mutagenesis of ATG4AGG of X protein start codon in the WPRE element (Quick change site-directed mutagenesis kit; Stratagene, La Jolla, CA, USA) (forward primer 5 0 -GGAAGCTGACGTCCTTTCCAGGGCTGCTCGCCTG TGTTGCC-3 0 and reverse primer 5 0 -GGCAACACAGG CGAGCAGCCCTGGAAAGGACGTCAGCTTCC-3 0 ). The mut6 element was generated by PCR as a 610-bp SalI/KpnI fragment from pBlue-SFFV-WPRE M8 (from Dr A Thrasher, Institute of Child Health, London, UK) (forward primer 5 0 -ACGCGTCGACAATCAACCTCTGG ATTACAA-3 0 and reverse primer 5 0 -GGGGTACCGAGC TCGAATTCGATGCGGGGA-3 0 ; 6 bp are mutated at the 5 0 end of WPRE and 2 bp at its 3 0 end; the reverse primer reconstitutes a 12-bp fragment of pRRL backbone, from the end of WPRE and KpnI restriction site). Such PCR fragment was cloned into the pLV-W lentiviral plasmid (pRRL SIN cPPT-WAS-WASp WPRE plasmid; kind gift from MG Roncarolo and Dr L Naldini, Tiget, Milan) to generate the pLV-W-W-WPRE(mut6). The mut6 WPRE fragment was excised from the latter construct with SalI/ SacII then ligated into pWPRE(WT)/aGFP digested with the same enzymes to generate the pWPRE(mut6)/aGFP plasmid. pdelta-WPRE/aGFP was obtained by SalI/SacII cleavage of pWPRE(WT)/aGFP, which was then blunted and self-ligated.
The pLV-W-W-WPRE(mut1) was generated by digesting the by SalI/SacII and ligated to the fragment obtained by SalI/SacII restriction of pBA-WPRE(mut1)/aGFP to generate pLV-W-W-WPRE(mut1). The pLV-W-W-delta-WPRE was obtained by SalI/KpnI restriction of pLV-W and ligation with a short double-strand synthetic SalI/ KpnI DNA fragment reconstituting the 12-bp of pLV-W from the end of WPRE to KpnI site (forward primer 5 0 -pTCGACGAATTCGAGCTCGGTAC-3 0 and reverse primer 5 0 -pCgAgCTCgAATTCg-3 0 ). The pLV-W-W-WPRE/aGFP was obtained by digesting pLV-W by SalI/KpnI and by ligating the WPRE fragment obtained by digestion of pLV-S-WPRE/aGFP with the same enzymes.
pLV-W-W-WPRE(mut1)/aGFP and pLV-W-W-WPRE (mut6)/aGFP were obtained by ligating each of the appropriate WPRE/aGFP fragment into pLV-W-W-WPRE(mut1) or (mut6) cleaved by the same enzymes. Finally, the pLV-W-W-delta-WPRE/aGFP was generated by SalI/SacII restriction and blunting of pLV-W-WPRE/ eGFP, which was then self-ligated.
Cell lines
The human cell lines 293T (kindly provided by Dr L Naldini), HCT116 and HepG2 cells (ATCC, Manassas, VA, USA) were grown in Dulbecco's modified Eagle's medium (Gibco BRL/Invitrogen, Cergy-Pontoise, France). The Epstein-Barr virus-transformed B-lymphoblastoid cell lines 589 and 04W derived from peripheral blood mononuclear cells of a normal individual or of a WAS patient were grown in RPMI 1640. 9 The 04W patient has a 1071 bp deletion in exon 3 to the end of intron 5. All media were supplemented with 10% heatinactivated fetal calf serum (FCS) (Hyclone, Logan, UT, USA), 50 IU ml À1 penicillin and 50 mg ml À1 streptomycin (Gibco BRL/Invitrogen) and cells were grown at 37 1C in a humidified atmosphere containing 5% CO 2 .
Production and titration of lentiviral vectors
LVs pseudotyped with the vesicular stomatitis G protein (VSV-G) were generated by transfection into 293T cells of a packaging construct pMDLgpRRE, a plasmid producing the VSV-G envelope (pMD.G), a plasmid containing the Rev-responsive element (RRE; pRSV-Rev) and the vector itself as previously described. 28 Culture medium was collected at 24, 48 and 72 h, pooled, 0.2 mm filtered, concentrated approximately 500-fold by ultracentrifugation, aliquoted and stored at À80 1C until used.
Viral titers (expressed in infectious genomes per milliliter, ig ml ) were determined by q-PCR (TaqMan chemistry, 29 ) following 2-h transduction with serial dilutions of the vector preparation of 10 5 HCT116 cells in a 12-well plate in the presence of 6 mg ml À1 polybrene (Sigma Aldrich, St Louis, MO, USA). After two medium changes (4 days after infection), genomic DNA from transduced cells was extracted using a genomic DNA purification kit (Promega Corporation, Madison, WI, USA). Proviral sequences were amplified at C and 3 0 -WPRE boundaries and normalized to the human albumin gene (hALB) intron 12, using primers described in Supplementary materials.
Standard curve with known amounts of DNA (quantified by optical density) from pRRLcpptPGKGFP_ WPRE_Alb (7539 bp) plasmid was used to quantify numbers of C WPRE and hALB molecules present in each sample. The number of igs per transduced cell was determined after normalization of C and WPRE with hALB assuming two alleles hALB per cell and two LTR per integration (for C determination). Titers in ig ml 
Lentiviral vectors transduction of cell lines
HCT116 cells were transduced with the LVs at the concentrations of either 1, 5 or 10 Â 10 7 ig ml À1 (multiplicity of infection (MOI), respectively, of 10, 50 and 100) for 2 h with 6 mg ml À1 polybrene. After two passages (10 days after infection), cells were analyzed for WASp, WHX protein and eGFP expression. B-LCL were transValidation of a mutated PRE MA Zanta-Boussif et al duced in the presence of polybrene (6 mg ml
À1
) for 6 h with various concentrations of vectors ranging from 0.5 to 25 Â 10 7 ig ml À1 with an MOI ranging from 5 to 100. After transduction, cells were washed and incubated for 7-10 days, adding fresh medium every other day.
Animals
All mice used for the BM transplants were housed at Genethon Animal Facility, Evry, France. Originally, 129/ Sv WKO mice were kindly provided by Dr Snapper (Massachusetts General Hospital, Boston, MA, USA) and have been bred either at Institut Gustave Roussy, Villejuif, France (INSERM U790) or at Genethon under pathogen-free conditions. WT 129 Sv/Ev mice were purchased from Iffa Credo (L'arbresle, France) and quarantined for at least 7 days before use.
Preparation, transduction and transplantation of progenitor cells
Lin
À cells were purified from WT or WKO BM cells as described earlier. 16 Lin À cells were preactivated by culture at 37 1C and 5% CO 2 for 1 day in X-Vivo 20 medium (BioWhittaker, Walkersville, NJ, USA) supplemented with 2% FCS, 2 mM L-glutamine, 50 ml À1 penicillin, 50 ng ml ) and cytokines for 6 h. Controls consisted of WKO Lin À cells and 129/Sv WT Lin À cells transduced with the LV-PGK-GFP vector under the same conditions. At the end of transduction, fresh medium was added and the following day, cells were washed and transplanted by infusing intravenously 5 Â 10 5 cells per mouse into lethally irradiated female WKO mice. Recipient female WKO mice were irradiated in ventilated Plexiglas containers using an X-ray source at a dose rate of 0.84 Gy min À1 (Faxitron). Total body irradiation was given as a single exposure of 9.5 Gy, 2-3 h before cell transplantation. A fraction of the cells was not injected in the mice and expanded in culture for 7 days in the presence of cytokines.
Evaluation of transduction and engraftment in treated mice
The efficiency of transduction was evaluated by analyzing VCN using qRT-PCR, WAS mRNA expression using qRT-PCR and WASp levels in transduced cells by western blot. The efficiency of transduction was evaluated in cultures of Lin À cells and in mice. One or two months after transplantation, blood was sampled by retro-orbital puncture to quantify the presence of vector in cells and to evaluate the percentages of male chimerism based on quantification of the male Y sequence as previously described. 16 Two, four or eight months after transplant, mice were killed by cervical dislocation to analyze the presence of vector and its expression in BM, spleen or thymus.
Quantitative PCR analyses of murine cells, tissues and of human cell lines
For blood cell analysis, genomic DNA was extracted by QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genomic DNA was extracted from murine tissue cells or from human cells using the 'Wizard genomic DNA purification kit' (Promega Corporation) and total RNA was extracted using SV total RNA isolation system (Promega Corporation). One microgram of each total RNA sample was reverse transcribed into cDNA with the Super-Script II RT (Gibco BRL) using random hexamer primers at 42 1C for 50 min. The RT was inactivated by incubation for 15 min at 70 1C.
The various q-PCR employed oligonucleotide primers and TaqMan probes listed in Supplementary materials and which were designed with Primer Express and Oligo 4.0 Primer Analysis software (PerkinElmer Applied Biosystems, Norwalk, CT, USA) and reactions were amplified and analyzed with an ABI PRISM 7700 sequence detector (PerkinElmer Applied Biosystems). TaqMan probes consisted of oligonucleotides with a 5 0 reporter dye (6-carboxyfluorescein) and a downstream 3 0 quencher dye (6-carboxytetramethyl rhodamine). Amplification reactions (17 ml) contained 8 ml of sample cDNA or genomic DNA and 9 ml of TaqMan buffer (TaqMan Universal PCR Master Mix, No AmpErase UNG; Applied Biosystems), 0.2 mM primers (forward and reverse) and 0.1 mM TaqMan probe and consisted of 40 cycles at 95 1C (15 s) then 60 1C (1 min). Standard amplification curves were obtained by serial dilutions of DNA containing appropriate sequences. All measures were performed at least in duplicate. Negative controls were included in each analysis. Data were edited using the Primer Express software.
In murine cells and tissues, VCN was measured by amplifying the WPRE sequence in reference to the murine TTN gene and results were calculated from a standard curve based on dilutions of a plasmid containing both the WPRE and mouse TTN sequences; 16 male and female chimerism was measured by quantification of murine Y sequence per cell in reference to the murine TTN gene and results were expressed as percentages of male cells in the population of cells tested and calculated based on mixtures of known proportions of male and female cells; the WAS mRNA was measured by qRT-PCR in reference to the murine TFIID gene expression and results were expressed as arbitrary units based on a standard control normalized to 1.0 (this standard consists of cells transduced with a pRRL vector and is comparable from one experiment to the other). In human cells, VCN was measured by amplifying the WPRE sequence in reference to the hALB gene and results were calculated from a standard curve based on dilutions of a plasmid containing both sequences; 9 WAS mRNA expression was measured in reference to either WPRE or to human TFIID or hPO and results were expressed as arbitrary units based on a standard normalized to 1.0 (for WAS/WPRE ratios this standard consisted of the pLV-W-W-WPRE(WT) plasmid, for WPRE/PO ratios the standard consisted of the LV PGK-GFP and for WAS/TFIID ratio this standard consisted of the cDNA from normal B-LCL).
Western blot analysis
The expression of human WASp in animal cells or in human cells by western blotting has already been Validation of a mutated PRE MA Zanta-Boussif et al reported. 9, 16 Transferred SDS-polyacrylamide gels were blotted with WASp-specific antibodies D1 clone (detecting mouse and human WASp) or B9 clone (detecting only human WASp in mouse cells), (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-b-actin antibody (Sigma Aldrich) and revealed with enhanced chemiluminescence western blotting detection kit and Kodak Biomax film.
Flow cytometric analysis
Cell suspensions from spleen were stained with fluorescently labeled antibodies and analyzed by flow cytometry using standard experimental conditions. Briefly, cells were incubated with the antibodies for 30 min, washed twice in phosphate-buffered saline (PBS) and analyzed with the LSR instrument using the DIVA software (Becton Dickinson, NJ, USA). Spleen cells were lysed with ACK (NH 4 Cl) and washed before staining with B220-APC (Pharmingen, San Diego, CA, USA). In human cell lines, the expression of GFP was measured by using the dual-laser FACSCalibur cytometer (Becton Dickinson) following addition of 7-amino-actinomycin D (7-AAD) for elimination of dead cells and results were analyzed using the CellQuest software (Becton Dickinson).
Detection of podosomes in BM-DC
Murine BM cells were cultured for 12-14 days in the presence of mouse granulocyte-macrophage colonystimulating factor to produce immature dendritic cells that were deposited onto glass coverslips coated with murine fibronectin (coated at 100 ng ml À1 for 4 h at 4 1C and washed with PBS). Cells were incubated onto fibronectin for 2 h at 37 1C, fixed in 2% paraformaldehyde for 10 min, washed with PBS and permeabilized using Triton X-100 (0.2%) for 4 min. Podosomes were detected by staining vinculin (1:400; Sigma Aldrich) detected with Alexa 488 goat anti-mouse (1:1000; Invitrogen (Molecular Probes reagents) and filamentous actin (tetramethylrhodamine-phalloidin, 1:1000). Nuclei were labeled with 4,6-diamidino-2-phenyl indole in the anti-fading mounting medium (Fluoromount G). Percent cells displaying podosomes were counted by enumerating at least 100 cells in confocal microscopy using a Leica TCS SP2 AOBS laser scanning microscope. Imaging was performed with a Â 40 oil-immersion objective using the laser wavelengths 488 nm (argon), 543 nm (HeNe) excitation and 405 nm (diode laser). All images represent a single section through the focal plane. Images were processed with Leica TCS Start and Adobe Photoshop software.
Colon histology
Colons were obtained from mice on killing and tissues were fixed in formalin, embedded in paraffin, sectioned and stained with hematoxylin eosin. Photographs were taken on an Axiophot (Zeiss) microscope with a Sensicam 12-bit cooled camera (PCO; Kelheim, Germany) using the integrated Camware software. Slides were read by a certified pathologist (PO) and the scoring system is detailed in the legend to Table 5 .
